Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3009373 | 0.85 | NR1H2 (0.37) | NR1H2NR1H3 | |
| SCHEMBL2012997 | 0.79 | — | — | |
| SCHEMBL3008366 | 0.74 | AR (0.32) | — | |
| SCHEMBL27780013 | 0.72 | NR1H2 (0.47) | NR1H2NR1H3 | |
| SCHEMBL2997348 | 0.71 | ALDH1A1 (0.40) | — | |
| SCHEMBL16524613 | 0.70 | — | — | |
| SCHEMBL18238741 | 0.70 | ACHE (0.40) | ACHENR1H2NR1H3 | |
| SCHEMBL2015446 | 0.70 | — | — | |
| SCHEMBL3006249 | 0.69 | — | — | |
| SCHEMBL5546191 | 0.68 | ACHE (0.35) | ACHENR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9809611-B2 | Carbonylation ligands and their use in the carbonylation of ethylenically unsaturated compounds | LUCITE INTERNATIONAL UK LIMITED (GB) | 2017-11-07 | — | — | US | claimed |
| US-20100113255-A1 | NOVEL CARBONYLATION LIGANDS AND THEIR USE IN THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS | LUCITE INTERNATIONAL UK LIMITED (GB) | 2010-05-06 | — | — | US | claimed |
| EP-2794548-B1 | A CONTINUOUS PROCESS FOR THE CARBONYLATION OF ETHYLENE | LUCITE INT UK LTD (GB) | 2019-05-15 | — | — | EP | disclosed |
| US-9809611-B2 | Carbonylation ligands and their use in the carbonylation of ethylenically unsaturated compounds | LUCITE INTERNATIONAL UK LIMITED (GB) | 2017-11-07 | — | — | US | disclosed |
| US-8445711-B2 | Metal complexes | LUCITE INTERNATIONAL UK LIMITED (GB) | 2013-05-21 | — | — | US | disclosed |
| US-20120309613-A1 | CARBONYLATION PROCESS | LUCITE INTERNATIONAL UK LIMITED (GB) | 2012-12-06 | — | — | US | disclosed |
| US-20100197958-A1 | PROCESS FOR THE CARBONYLATION OF AN ETHYLENICALLY UNSATURATED COMPOUND AND A CATALYST SYSTEM | LUCITE INTERNATIONAL UK LIMITED (GB) | 2010-08-05 | — | — | US | disclosed |
| US-20100113255-A1 | NOVEL CARBONYLATION LIGANDS AND THEIR USE IN THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS | LUCITE INTERNATIONAL UK LIMITED (GB) | 2010-05-06 | — | — | US | disclosed |
| US-20090312561-A1 | METAL COMPLEXES | LUCITE INTERNATIONAL UK LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197958-A1 | PROCESS FOR THE CARBONYLATION OF AN ETHYLENICALLY UNSATURATED COMPOUND AND A CATALYST SYSTEM | ALOX5, ACSL5, ELOVL5 | ACHE 1088/4885NR1H2 329/4885NR1H3 369/4885 |
| US-20090312561-A1 | METAL COMPLEXES | MLX, PICALM, AP2M1 | ACHE 1503/4885NR1H2 4064/4885NR1H3 3761/4885 |
| US-20100113255-A1 | NOVEL CARBONYLATION LIGANDS AND THEIR USE IN THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS | PRDX1, PRDX4, PRDX2 | ACHE 2305/4885NR1H2 674/4885NR1H3 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.